Invictus MD enters into a LOI to acquire Las Vegas cultivation license

Posted on Categories: Investor Relations

Vancouver, BC, October 27, 2016 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has entered into a Letter of Intent for an option to acquire 10% in an unnamed State of Nevada (“SNV”) Medical Marijuana Cultivation License located in Las Vegas NV (‘The Seller”) for $2,250,000 USD by way of issuance of common shares of Invictus MD based on the VWAP of Invictus MD three (3) days prior to closing the definitive agreement.

The terms of the Letter of Intent allows Invictus MD to exercise its option within 45 days after The Seller has obtained its final approval for cultivation from The SNV inspection department. A preliminary inspection date has been booked for late 2016 and the final cultivation license is expected to be issued in Q1 of 2017. Upon issuance of the cultivation license, Invictus MD will have the option to acquire a 10% equity stake from The Seller, with the option to exercise another 50% (totalling 60%) expiring within 6 months of signing the definitive agreement. The transaction is subject to the SNV approval.

Dan Kriznic, CEO of Invictus MD, commented, “The City of Las Vegas has always been on our radar, as it is one of few states which allow for reciprocity of licenses. Meaning anyone in the world holding a medical marijuana prescription card will be able to purchase cannabis here. Las Vegas being the number 1 tourist destination in all of the U.S., we feel that this market has tremendous potential, with one of the toughest barriers of entry. We chose to close this transaction before the recreational ballot vote on November 8th, 2016 as we feel The Seller would ask for an increase in valuation if recreational wins the ballot.”
Invictus MD also announces that a total of 450,000 incentive stock options have been granted to officers and directors of the Company pursuant to the Company’s Stock Option Plan. The options are exercisable for a period of five years at a price of $0.92 per share.

About Invictus MD Strategies Corp.

Invictus MD targets companies with proven brands, strong customer focus, and significant growth potential. We provide not only capital to meet these objectives but also years of management experience from a team that has been successful in all facets of business, from establishing start-ups to running large international organizations. The fundamental core of our operations centers on the vast opportunities within fragmented industries.

Invictus MD works in partnership with management teams to increase shareholder value through business planning and process integration, developing and executing growth strategies, leveraging our experience and relationships, and structuring and deploying the proper capital to support long-term growth. Our prudent approach to both investing in and developing successful companies ensures successful execution of the business plan in both times of economic expansion and contraction.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,

Dan Kriznic
Chairman & CEO
604-368-6437

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements

Invictus MD enters into a LOI to acquire Cannabis Testing Laboratory

Posted on Categories: Investor Relations

Vancouver, BC, October 24, 2016 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has entered into a Letter of Intent for an option to acquire 49% of Zenalytic Laboratories Inc. (“Zen Labs”), a wholly owned subsidiary of the GreenTec BioPharmaceuticals Corporation Group (“GreenTec”), for $300,000 CDN by way of issuance of common shares of Invictus MD based on the VWAP of Invictus MD three (3) days prior to closing the definitive agreement.

The terms of the Letter of Intent allows Invictus MD to exercise its option within 45 days after Zen Labs has obtained its Section 56 Class Exemption Dealer’s license (“The License”) from Health Canada under the Narcotic Control Regulations, in which Zen Labs will be licensed and authorized to conduct analytical testing services for dried marijuana, fresh marijuana and cannabis extracts from individuals and Licensed Producers authorized under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) as well as those authorized within the Marihuana Medical Access Regulations (“MMAR”) that were repealed on March 31, 2014. Invictus MD will pay a nonrefundable deposit of $45,000 to Zen Labs on closing of the option agreement by way of issuance of common shares of Invictus MD based on the VWAP of Invictus MD three (3) days prior to closing the option agreement.

Zen Lab’s Dealers License application #6-939 was confirmed in writing for acceptance on July 27th, 2016 by The Office of Controlled Substances – Controlled Drugs Section Authorizations Division, based on a 1500 square foot laboratory that has already been fully built with an operating business license issued by the City of Kelowna. While awaiting its Section 56 Class Exemption Dealer’s license from Health Canada, Zen Labs is revenue generating as a fully functioning microbial and environmental analytical testing laboratory (more information about Zen Labs’ various testing capabilities can be found on www.zenlabs.ca).

The Office of Controlled Substances has confirmed in writing that Zen Labs will receive a decision within 180 days of acceptance. If there are no deficiencies within the application, Zen Labs is expected to be licensed by February 2017. Zen Labs has over $500,000 CAD dollars spent to date on construction and laboratory equipment including (but not limited to):

  • HPLC (High Performance Liquid Chromatography)
  • GC-FID (Gas Chromatography Flame Ionization Detector)
  • GC-MS (Gas Chromatography Mass Spectrometer)
  • ICP-MS (Inductively Coupled Plasma Mass Spectrometer)
  • ICP-OES (Inductively Coupled Plasma Optical Emission Spectrometer)
  • IC (Ion Chromatography)
  • Pathogen and Toxin license (risk group 2 human and animal pathogens)
  • TheraCanSYSTEM Enterprise Relational Process (ERP) ISO 17025(2005) and Safe Quality Food (SQF) compliant Web based software that provides the Laboratory Information Management System (LIMS) required by Health Canada for traceability and auditability of Zen Labs’ sample handling.
  • A secure and encrypted off-site private server to store data and information for auditability by Health Canada and the Zen Labs’ QPICs.
  • A state of the art and compliant security system with a Level 7 vault (currently in construction) designed and installed by Paladin / BMS.

Norton Singhavon, President & ICP of Zenalytic Laboraties, commented, “This partnership with Invictus MD will allow Zen Labs and GreenTec to utilize the tremendous amount of contacts and business acumen that the team at Invictus will bring to our group. We feel that this is just the beginning of a partnership and we are extremely excited to partner on future ventures with the Invictus MD team.”

Dan Kriznic, CEO of Invictus MD, commented, “With the recent ACMPR regulations announcing that those individuals authorized under the ACMPR and MMAR are now authorized to send cannabis and cannabis extracts for testing to an approved analytical lab, this ancillary vertical will be a rapidly emerging business as our clients will range from the small at-home grower to the billion-dollar corporate Licensed Producer. This will complement Future Harvest Development (“FHD”) as it will provide many cross relationships for Zen Labs’ clients who are cultivating and extracting cannabis. This will open doors and opportunities to promote FHD’s fertilizers and also enables FHD’s existing clients to have a reputable analytical laboratory confirm that their final product will be low in heavy metals and urea-free. With Zen Labs being located just 8 km from FHD, we will also have access to accurately analyze our fertilizers for metals and microbial content.”

About Zenalytic Laboratories Inc.
Zenalytic Laboratories (www.zenlabs.ca) was formed in May 2015. It is currently a wholly owned subsidiary of the GreenTec Bio-Pharmaceuticals Corporation Group (“GreenTec”), who is an applicant to become a Licensed Producer, under the Access to Cannabis for Medical Purposes Regulations (ACMPR) application #MM-0658. GreenTec has been in Security Clearance since April 19th, 2016 and is expected to clear security clearance and enter Enhanced Review by late 2016 or early 2017.

While waiting for Health Canada to complete its approval process, two of GreenTec’s R/PIC’s Aaron Godin and Professor Michael Deyholos have played vital roles in the formation of Zen Labs and becoming the Quality Person(s) in Charge (QPIC).

Aaron Godin (Q/PIC) has over 10 years of research experience in soil biogeochemistry, studying the microbiological, physical, and chemical factors that mediate nutrient cycling. He has worked as a lab technician at both the Ontario Forest Research Institute and the Summerland Research and Development Centre (formally the Pacific AgriFood Research Centre).

Aaron has been involved in the medical marijuana industry since 2014, working as a cultivation expert and QA/QC person. He is the lab manager at Zen Labs. Aaron completed his B.Sc. in Biology and Environmental Science at the University of Toronto and his M.Sc. in Biology at the University of British Columbia. Aaron is also currently working with a leading SFE equipment manufacturer Vitalis Extraction Technologies (www.vitalisET.com) to strengthen his quality assurance and control skill-set when working with commercial equipment used to process cannabis; specifically working with the Vitalis 45L SFE CO2 oil extraction machine.

Michael Deyholos (A/QPIC) is Professor and Head of Biology at the University of British Columbia, Okanagan campus. Prior to coming to UBCO, he was a Professor in the Department of Biological Sciences at the University of Alberta, where he worked with the genetics of industrial hemp (Cannabis sativa).

He holds a Ph.D. in Plant Molecular Biology from McGill University (2000), and completed postdoctoral work at the University of Arizona.

About Invictus MD Strategies Corp.

Invictus MD targets companies with proven brands, strong customer focus, and significant growth potential. We provide not only capital to meet these objectives but also years of management experience from a team that has been successful in all facets of business, from establishing start-ups to running large international organizations. The fundamental core of our operations centers on the vast opportunities within fragmented industries.

Invictus MD works in partnership with management teams to increase shareholder value through business planning and process integration, developing and executing growth strategies, leveraging our experience and relationships, and structuring and deploying the proper capital to support long-term growth. Our prudent approach to both investing in and developing successful companies ensures successful execution of the business plan in both times of economic expansion and contraction.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,

Dan Kriznic Chairman & CEO

604-368-6437

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed spin-out of Future Harvest, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the proposed spin-out of Future Harvest will occur as anticipated, that the Company will obtain all requisite approvals of the spin-out transaction, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed spin-out may not occur as planned; the timing and receipt requisite approvals. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forwardlooking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbour.

 

Future Harvest Collaborates with UBC Kelowna to Progress Plant Growth

Posted on Categories: Investor Relations

Vancouver, BC, October 21, 2016 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that Future Harvest Development Ltd. (“Future Harvest”), is working directly with The University of British Columbia Kelowna Campus (“UBC Kelowna”) to secure grants for various topics in plant research. One such research grant that Future Harvest helped procure focuses on increasing the effectiveness of Lavender plants flowering in an artificially controlled environment. Future Harvest has recently assisted in planning, building and equipping an indoor grow lab at UBC Kelowna using Future Harvest plant nutrients. This grow lab will be a permanent fixture at the UBC Kelowna campus for years to come, giving researchers and students alike, a precisely controlled environment to carry out their research.

“Future Harvest places tremendous value in agricultural research & development.” explained Dr. Soheil Mahmoud, Associate Professor of Biology at the University of British Columbia’s Okanagan campus. “It was delightful to witness both passion and commitment to product efficacy in my lavender research collaboration with this company.”

“Cannabis and lavender share many rare biochemical and anatomical similarities including their ability to produce large amounts of terpene-related specialized metabolites (monoterpenes) in glandular trichomes.” explains Chris Pearson, Chief Revenue Officer of Future Harvest, “Through this research partnership, we are better able to understand the impact of FHD PlantLife proprietary nutrients in the development of these metabolites, (which include THC, CBD, and other critical cannabinoids and secondary metabolites) providing us with the critical data required to formulate cutting edge fertilizer formulations specifically for the production of
Cannabis. Future Harvest looks forward to continue to build its relationship with UBC and the Kelowna campus. The organizations will be working together to create new innovative products and data that are beneficial for plant production and flowering.”

As previously announced, the Company intends to complete a spin-out of Future Harvest into a newly formed public company (“NewCo”) in January 2017, subject to shareholder and regulatory approval. As part of the spin-out, shareholders of the Company will receive one share in NewCo for every one share held in Invictus MD. Invictus MD is continuing to seek investments and partnership opportunities in the cannabis space while working on the commercialization of Poda Vape Technologies Ltd.

About Future Harvest Development Ltd.
For over 20 years, Future Harvest has brought innovative products and solutions to the
hydroponic and indoor growing industries. Future Harvest’s product lines are available
through leading distributors and retailers across North America, the United Kingdom
and Europe and include Nutradip, Plantlife Products and Future Harvest Plastics.

Future Harvest has been manufacturing metering and monitoring equipment for over fifteen years. The most popular and industry standard is the Trimeter, made famous because a single glance tells you if your pH, nutrients and temperatures are on target. All Nutradip products are developed, designed, tested and assembled in Canada.

Plantlife Products consists of 29 proprietary formulas that offer growers the leading edge in sediment free plant nutrition. Every product has been developed and tested inhouse by Future Harvest’s own plant scientists.

For more information please visit www.futureharvest.com.

About Invictus MD Strategies Corp.
Invictus MD targets companies with proven brands, strong customer focus, and
significant growth potential. We not only provide capital to meet these objectives but also years of management experience from a team that has been successful in all facets of business from start-ups to running large international organizations. The fundamental core of our operations is centered on the vast opportunities within fragmented industries.

Invictus MD works in partnership with management teams to increase shareholder value through business planning and process integration, developing and executing growth strategies, leveraging our experience and relationships, and structuring and deploying the proper capital to support long-term growth. Our prudent approach to both investing in and developing successful companies ensures successful execution of the business plan in both times of economic expansion and contraction.

For more information please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Chairman & CEO
604-368-6437

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed spin-out of Future Harvest, are forward-looking statements
and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the proposed spin-out of Future Harvest will occur as anticipated, that the Company will obtain all
requisite approvals of the spin-out transaction, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed spin-out may not occur as planned; the timing and receipt requisite approvals. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbour.

Invictus MD announces $1 million Dividend

Posted on Categories: Investor Relations

Vancouver, BC, October 11, 2016 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that its Board of Directors have approved the payment of a cash dividend of $1 million. This represents $0.108 per share based on the current number of shares issued and outstanding of 9,238,805. The dividend is payable on Monday November 24th, 2016 to shareholders of record as of Thursday November 10th, 2016. The dividend per share may be greater or lesser than $0.108 based on the number of shares issued and outstanding as of the record date.

Dan Kriznic, CEO of Invictus MD commented, “We have now finalized the sale of our Sunblaster division previously owned by Future Harvest Developments Ltd. This sale provided us with cash in excess of what is required to execute our business plan. Future Harvest generates positive cash flow and has recently upgraded all of its equipment to meet the significant fertilizer demand from its customers.”

As previously announced, the Company intends to complete a spin-out of Future Harvest into a newly formed public company (“NewCo”) in January 2017, subject to shareholder and regulatory approval. As part of the spin-out, shareholders of the Company will receive one share in NewCo for every one share held in Invictus MD.

About Future Harvest Development Ltd.
For over 20 years, Future Harvest has brought innovative products and solutions to the hydroponic and indoor growing industries. Future Harvest’s product lines are available through leading distributors and retailers across North America, the United Kingdom and Europe and include Nutradip, Plantlife Products and Future Harvest Plastics.

Future Harvest has been manufacturing metering and monitoring equipment for over fifteen years. The most popular and industry standard is the Trimeter, made famous because a single glance tells you if your pH, nutrients and temperatures are on target. All Nutradip products are developed, designed, tested and assembled in Canada.

Plantlife Products consists of 29 proprietary formulas that offer growers the leading
edge in sediment free plant nutrition. Every product has been developed and tested inhouse
by Future Harvest’s own plant scientists.

For more information please visit www.futureharvest.com.

About Invictus MD Strategies Corp.
Invictus MD targets companies with proven brands, strong customer focus, and significant growth potential. We not only provide capital to meet these objectives but also years of management experience from a team that has been successful in all facets of business from start-ups to running large international organizations. The fundamental core of our operations is centered on the vast opportunities within fragmented industries.

Invictus MD works in partnership with management teams to increase shareholder
value through business planning and process integration, developing and executing
growth strategies, leveraging our experience and relationships, and structuring and
deploying the proper capital to support long-term growth. Our prudent approach to
both investing in and developing successful companies ensures successful execution of
the business plan in both times of economic expansion and contraction.

For more information please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman & CEO
604-368-6437

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed spin-out of Future Harvest, are forward-looking statements
and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the proposed spin-out of Future Harvest will occur as anticipated, that the Company will obtain all requisite approvals of the spin-out transaction, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed spin-out may not occur as planned; the timing and receipt requisite approvals. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forwardlooking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbour.